An open-label randomized trial of zanidatamab with standard-of-care therapy against standard-of-care therapy alone for advanced HER2-positive biliary tract cancer (BTC)
This study is testing a new treatment called zanidatamab to see how well it works and how safe it is for people with a type of cancer called HER2-positive biliary tract cancer (BTC), which affects the gallbladder and bile ducts and cannot be removed by surgery or has spread to other parts of the body. Participants may receive up to two cycles of chemotherapy (cisplatin and gemcitabine, or “CisGem”) before being randomly assigned to one of two groups. In Group A, participants will get zanidatamab plus CisGem, with or without an immune therapy drug (like durvalumab or pembrolizumab). In Group B, participants will get CisGem, with or without the immune therapy drug. The treatment will continue until the cancer gets worse.
An Open-label Study to Evaluate the Safety Tolerability Pharmacokinetics and Pharmacodynamics of EDG-7500 in Adults with Hypertrophic Cardiomyopathy
The purpose of this study is to learn about the safety and tolerability of an investigational study drug called EDG-7500 for the treatment of hypertrophic cardiomyopathy (HCM). The study will also measure levels of study drug and any possible metabolites (break-down products of the study drug) and biological markers (biomarkers) in the blood. Biomarkers are substances in your blood that help us understand how the body is reacting to the study drug.
AN OPEN-LABEL TREATMENT WITH RANDOMIZATION OBSERVATION INVESTIGATOR-INITIATED STUDY ON THE DURATION AND EFFICACY OF JORNAY PM (METHYLPHENIDATE HYDROCHLORIDE EXTENDED-RELEASE CAPSULES) ON ADULT ADHD SYMPTOMS AND EXECUTIVE FUNCTION AND EMOTIONAL REGULATION THROUGHOUT THE DAY INTO EARLY EVENING
The purpose of this research study is to examine the efficacy of Jornay PM on Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms and Executive Function throughout the day into early evening. This study will last approximately 11 weeks with will involve about 11 visits that are conducted both remote (WebEx/Telephone) and in the clinic.
Andrew W. Brotman, MD | NYU Langone Health
Andrew W. Brotman is senior advisor to CEO and Dean Alec C Kimmelman, MD, PhD.
Anesthesiology Doctors | NYU Langone Health
View all NYU Langone doctors who specialize in anesthesiology.
Angelman Syndrome Clinic | NYU Langone Health
The Angelman Syndrome Clinic at NYU Langone’s Comprehensive Epilepsy Center provides expert care for people with Angelman syndrome.
Angina with No Blockage | NYU Langone Health
NYU Langone doctors diagnose and treat chest discomfort (angina) with no blockage, also known as ischemia with no obstructive coronary artery disease (INOCA).
Anita Saltz Institute for Anxiety & Mood Disorders | NYU Langone Health
The Anita Saltz Institute for Anxiety and Mood Disorders at NYU Langone’s Child Study Center treats depression in children and adolescents.
Annette Johnson, JD, PhD | NYU Langone Health
Annette Johnson, JD, PhD, is executive vice president and vice dean, general counsel, at NYU Langone.
Anomalous Aortic Origin of a Coronary Artery (AAOCA): Establishing a Multi-Institutional Registry
This is a retrospective and longitudinal cohort study. Subjects will be enrolled either when identified from medical records or when diagnosed with AAOCA. Baseline demographics, diagnoses, and test results will be obtained through retrospective chart review. Follow-up health-related information will be obtained through annual questionnaire. The project will be carried out at several participating CHSS member institutions, with the data stored and analyzed at the CHSS Data Center.